section name header

Pronunciation

ma-ra-VI-rok

Classifications

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: ccr5 co.receptor antagonists

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 2–33% absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver by the CYP3A isoenzyme; 8% renal excretion as unchanged drug.

Half-life: 14–18 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown0.5–4 hr1–2 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: myocardial ischemia/infarction, orthostatic hypotension.

Derm: DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS.

GI: abdominal pain, appetite disorder, HEPATOTOXICITY.

MS: musculoskeletal pain.

Neuro: dizziness.

Resp: cough, upper respiratory tract infection.
Misc: fever, risk of infection, hypersensitivity reactions (including lip swelling and facial edema), immune reconstitution syndrome.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

Renal Impairment

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Selzentry

Canadian Brand Names

Celsentri